- Home
- MKTW vs VTVT Comparison
MKTW vs VTVT Comparison
Compare MKTW & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | VTVT |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 54.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MKTW | VTVT |
|---|---|---|
| Price | $16.16 | $26.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $20.00 | ★ $37.00 |
| AVG Volume (30 Days) | 9.4K | ★ 12.6K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $342,206,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.08 | $13.15 |
| 52 Week High | $21.74 | $33.16 |
Technical Indicators
Market Signals| Indicator | MKTW | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 49.33 |
| Support Level | $15.85 | $26.55 |
| Resistance Level | $16.50 | $32.53 |
| Average True Range (ATR) | 0.46 | 1.97 |
| MACD | -0.05 | -0.53 |
| Stochastic Oscillator | 19.66 | 12.22 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.